What are the indications for PMRT in an ER/PR(+) Her-2(-) patient with a complete pathologic response in the nodes after neoadjuvant chemo, but with residual disease in the breast?
Answer from: Radiation Oncologist at Academic Institution
This is an area where there is still a paucity of information. Hence, all guidelines need to be very tentative.
I recommend PMRT for all patients having biopsy-proven axillary node involvement prior to chemotherapy, as I am concerned these are the patients at highest risk of local-regional failure....
Comments
Radiation Oncologist at Washington University in St Louis I also include patients with cT1-2cN1 or cT3cN0-1 ...
Radiation Oncologist at University of Colorado School of Medicine Agree with @Abram Recht except for the cT3N0, thou...
Answer from: Radiation Oncologist at Academic Institution
Subject to ongoing/completed NSABP B-51.
Off trial, will get different answers based on whom you talk to.
In our practice, would offer if pre chemo was T3 or N2 disease or residual disease more than 2 cm in breast.
Comments
Radiation Oncologist at Sarasota Memorial Hospital How does ypTis disease influence decision to offer...
I also include patients with cT1-2cN1 or cT3cN0-1 ...
Agree with @Abram Recht except for the cT3N0, thou...